Lung delivery of non‐CFC salbutamol via small volume metal spacer and large volume plastic spacer devices compared with an open vent jet nebulizer
- 1 February 1998
- journal article
- clinical trial
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 45 (2) , 160-163
- https://doi.org/10.1046/j.1365-2125.1998.00648.x
Abstract
To compare the lung delivery of salbutamol from a commonly used constant output open vent jet nebuliser (Sidestream) with use of both a conventional large volume plastic spacer (Volumatic) and a novel small volume metal spacer (NebuChamber). This was assessed using the early lung absorption profile of salbutamol over the first 20 min after inhalation. Twelve healthy volunteers were studied in a randomized single (investigator) blind crossover design. Single 1200 microg nominal doses salbutamol from a CFC-free metered-dose inhaler (12 sequential 100 microg puffs of Airomir) were delivered via the Volumatic and NebuChamber spacers. A single 1200 microg nominal dose of salbutamol was given as a 4 ml fill volume from a Sidestream nebuliser with mouthpiece. Mouth rinsing was performed after each drug sequence. Plasma salbutamol was measured at 5, 10, 15 and 20 min after the last dose of each inhalation sequence, with calculation of maximal concentration (Cmax) and average concentration over 20 min (C[av]). Systemic beta2-responses were measured as plasma potassium, tremor and heart rate. Both the Volumatic and the NebuChamber spacers produced significantly greater salbutamol concentration than the Sidestream nebuliser. For C(av) this amounted to a 7.34-fold difference (95%CI 5.31 to 9.38) between Volumatic vs Sidestream, and a 7.04-fold difference (95%CI 4.91 to 9.17) for NebuChamber vs Sidestream. Similar differences were found for the extrapulmonary beta2-responses. There were no significant differences in either salbutamol concentration or extrapulmonary beta2-responses between the Volumatic and NebuChamber spacers. We found that, in vivo, both the Volumatic and the NebuChamber spacers produced seven-fold greater lung delivery of salbutamol than the Sidestream nebuliser when comparing microgram equivalent nominal doses, in terms of the early lung absorption profile.Keywords
This publication has 17 references indexed in Scilit:
- Effect of multiple actuations, delayed inhalation and antistatic treatment on the lung bioavailability of salbutamol via a spacer device.Thorax, 1996
- Effect of electrostatic charge, flow, delay and multiple actuations on the in vitro delivery of salbutamol from different small volume spacers for infants.Thorax, 1996
- Lung bioavailability of generic and innovator salbutamol MDIs.Thorax, 1996
- Lung bioavailability of chlorofluorocarbon free, dry powder and chlorofluorocarbon containing formulations of salbutamolBritish Journal of Clinical Pharmacology, 1996
- Lung bioavailability of generic and innovator salbutamol metered dose inhalers.Thorax, 1996
- A non-electrostatic spacer for aerosol delivery.Archives of Disease in Childhood, 1995
- The effect of delay, multiple actuations and spacer static charge on the in vitro delivery of budesonide from the Nebuhaler.British Journal of Clinical Pharmacology, 1995
- A Comparison of Commercial Jet NebulizersChest, 1994
- Emergency Department Treatment of Severe AsthmaChest, 1993
- Spacer Devices Used with Metered-Dose InhalersChest, 1985